Carfilzomib Plus Dexamethasone in Previously Treated Multiple Myeloma

On January 21, 2016, carfilzomib (Kyprolis) was approved for use in combination with dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.

 The ASCO Post

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.